Skip to main content
Premium Trial:

Request an Annual Quote

DiscernDx Acquires Luminist Labs

NEW YORK — DiscernDx said on Wednesday that it has acquired Luminist Labs, a privately held developer of diagnostic technology for nonalcoholic steatohepatitis (NASH) and other liver diseases.

Terms of the deal were not disclosed.

Founded in 2017, Palo Alto, California-based DiscernDx is building a platform that combines individualized clinical and molecular data in order to help guide treatment decisions. The company said it will integrate Luminist's technology into its platform to enhance its application in NASH and other chronic metabolic diseases.

Luminist is based in Newark, California.

"Our platform measures and interprets the dynamic changes in our bodies to provide personalized health insights," DiscernDx Cofounder and CEO Bruce Wilcox said in a statement. “The application of our proprietary multiomics platform to the unique sample and dataset created by Luminist Labs is expected to result in novel non-invasive diagnostic and prognostic solutions for patients living with NASH."

In early 2018, DiscernDx acquired the assets of Applied Proteomics for $1.85 million, primarily to gain access to that company's mass spectrometry technology and workflows.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.